The prescription did not help, and you concluded that the problem must be worse than you thought.
It is worth considering a different explanation: that the prescription was aimed at a system that was working fine.
If your difficulty is that you no longer particularly want to—rather than that you cannot—then a medication that improves blood flow was never going to change anything. There was nothing wrong with the blood flow.
At YoungerMeMD it is prescribed as the PT-141 therapy.
Two systems, two failures
Sexual response has a signal and a response.
The signal is desire—the initiating impulse, generated in the brain.
The response is largely vascular and largely downstream of the signal.
Those fail independently. A vascular failure with desire intact is one problem. A loss of desire is a different one, and it is upstream of everything the familiar medications act on.
The oral ED medications work on the vascular system. They improve the capacity to respond. They require desire to already be present—given the signal, they help the body act on it. Absent the signal, there is nothing for them to enable.
Which is why they can fail completely without indicating anything about how severe your problem is. Wrong system, not worse condition.
Naming the actual complaint
Reduced desire is oddly hard to describe, and most people never say it out loud, which is part of why it goes untreated.
It is not usually distress in the moment. It is the absence of the thought beforehand. The situation arises and you find that you are not really bothered either way—and it has been like that for long enough that you have stopped noticing when it changed.
For women the equivalent has a clinical name. Hypoactive sexual desire disorder—a persistent loss of desire that causes distress—and it is what PT-141 is FDA-approved for, in premenopausal women without underlying medical, psychiatric, or relationship causes, marketed as Vyleesi.
Men have no equivalent household term for it, which is one reason the conversation defaults to erectile difficulty even when that is not the problem.
Before the peptide: what else does this
This section comes before the therapy on purpose, because several causes of low desire are more treatable than a peptide and are commonly missed.
Hormones. Testosterone decline in men produces reduced desire directly, as does the broader hormonal picture in women, and thyroid dysfunction in both. Hormone optimization is a different and often more appropriate intervention, and we offer it.
Medication. Several common classes reduce desire—antidepressants prominently. If the change coincided with starting something, that is the first thing to examine.
Depression, which reduces desire as a core feature rather than as a side effect.
Chronic stress and sleep deprivation, both of which reduce desire reliably.
And relationship or psychological factors. The FDA indication for PT-141 explicitly excludes these—it is for HSDD without underlying medical, psychiatric, or relationship causes. When an approval is defined by its exclusions, that is telling you the diagnosis matters as much as the drug.
Working through that list is what a proper evaluation is for, and it is the reason to have one rather than to order something.
What PT-141 does
Where the assessment does point to a desire problem without another cause, there is a therapy aimed at exactly that.
PT-141 (Bremelanotide) works through the nervous system rather than the vascular system, by activating melanocortin receptors—pathways in the brain governing arousal and desire.
It functions through the nervous system to help restore sexual desire itself, activating pathways in the brain to improve desire and function.
For men: it targets the nervous system to increase desire rather than acting on the vascular system, and because it uses a different pathway, it can work for men who have not had success with other treatments.
In clinical trials it demonstrated meaningful improvements in desire, arousal and satisfaction.
Its origin is worth a line: PT-141 was derived from Melanotan II, a synthetic peptide hormone originally intended to darken skin pigmentation. Its effects on sexual function were discovered during early clinical research—the melanocortin receptor family turning out to be involved in both.
For women, including after menopause
PT-141 is FDA-approved for generalized HSDD in premenopausal women, where trials showed meaningful improvements in desire, arousal and satisfaction.
We also use it off-label for postmenopausal women with excellent results, and the mechanistic reason is significant: its mechanism is independent of estrogen status.
Much of what changes for women after menopause is estrogen-driven, and interventions aimed at those changes depend on hormonal context. A therapy acting on melanocortin receptors in the brain does not—which makes it available in a situation where many options are not.
How it is used
A small subcutaneous injection into fatty tissue of the lower abdomen or thigh, taken ahead of anticipated activity rather than daily. We instruct you at the office, and you can then keep the medication refrigerated and self-administer as recommended. We give you the timing and usage guidance.
It is an occasional therapy rather than a daily one—a different commitment from most of what this clinic prescribes.
What it does not do
It does not treat a vascular problem. If desire is intact and the physical response is not, that is the other system, and the oral medications are aimed at it.
It does not replace hormone therapy where a hormonal cause is identified.
It does not resolve psychological or relationship causes—the indication explicitly excludes them.
And it is not appropriate for everyone. It is prescribed after clinical evaluation, sourced from fully vetted, FDA-regulated compounding pharmacies and dispensed under physician supervision.
The most useful thing to establish is which of the two systems has changed—and, before treating either, whether something more ordinary is responsible.
That is a conversation worth having properly, and it is a more productive one than another prescription aimed at the wrong mechanism.
This article is for general education and is not medical advice. Reduced sexual desire has many causes—hormonal, psychological, medication-related and others—several of which require medical evaluation. Erectile difficulty can also indicate cardiovascular and other conditions. PT-141 is FDA-approved for generalized hypoactive sexual desire disorder in premenopausal women without underlying medical, psychiatric or relationship causes; use in men and in postmenopausal women is off-label. It is a physician-supervised prescription therapy and is not appropriate for everyone.
